Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants

Abstract Differences in innate immune ‘imprinting’ between vaccine adjuvants may mediate dissimilar effects on the quantity/quality of persisting adaptive responses. We compared antibody avidity maturation, antibody/memory B cell/CD4+ T cell response durability, and recall responses to non-adjuvante...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sonia Budroni, Francesca Buricchi, Andrea Cavallone, Patricia Bourguignon, Magalie Caubet, Vincent Dewar, Ugo D’Oro, Oretta Finco, Nathalie Garçon, Mohamed El Idrissi, Michel Janssens, Geert Leroux-Roels, Arnaud Marchant, Tino Schwarz, Pierre Van Damme, Gianfranco Volpini, Robbert van der Most, Arnaud M. Didierlaurent, Wivine Burny
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/44c6adaabe024a3786359666e5ee13fc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:44c6adaabe024a3786359666e5ee13fc
record_format	dspace
spelling	oai:doaj.org-article:44c6adaabe024a3786359666e5ee13fc2021-12-02T15:52:54ZAntibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants10.1038/s41541-021-00337-02059-0105https://doaj.org/article/44c6adaabe024a3786359666e5ee13fc2021-05-01T00:00:00Zhttps://doi.org/10.1038/s41541-021-00337-0https://doaj.org/toc/2059-0105Abstract Differences in innate immune ‘imprinting’ between vaccine adjuvants may mediate dissimilar effects on the quantity/quality of persisting adaptive responses. We compared antibody avidity maturation, antibody/memory B cell/CD4+ T cell response durability, and recall responses to non-adjuvanted fractional-dose antigen administered 1-year post-immunization (Day [D]360), between hepatitis B vaccines containing Adjuvant System (AS)01B, AS01E, AS03, AS04, or Alum (NCT00805389). Both the antibody and B cell levels ranked similarly (AS01B/E/AS03 > AS04 > Alum) at peak response, at D360, and following their increases post-antigen recall (D390). Proportions of high-avidity antibodies increased post-dose 2 across all groups and persisted at D360, but avidity maturation appeared to be more strongly promoted by AS vs. Alum. Post-antigen recall, frequencies of subjects with high-avidity antibodies increased only markedly in the AS groups. Among the AS, total antibody responses were lowest for AS04. However, proportions of high-avidity antibodies were similar between groups, suggesting that MPL in AS04 contributes to avidity maturation. Specific combinations of immunoenhancers in the AS, regardless of their individual nature, increase antibody persistence and avidity maturation.Sonia BudroniFrancesca BuricchiAndrea CavallonePatricia BourguignonMagalie CaubetVincent DewarUgo D’OroOretta FincoNathalie GarçonMohamed El IdrissiMichel JanssensGeert Leroux-RoelsArnaud MarchantTino SchwarzPierre Van DammeGianfranco VolpiniRobbert van der MostArnaud M. DidierlaurentWivine BurnyNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 6, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Sonia Budroni Francesca Buricchi Andrea Cavallone Patricia Bourguignon Magalie Caubet Vincent Dewar Ugo D’Oro Oretta Finco Nathalie Garçon Mohamed El Idrissi Michel Janssens Geert Leroux-Roels Arnaud Marchant Tino Schwarz Pierre Van Damme Gianfranco Volpini Robbert van der Most Arnaud M. Didierlaurent Wivine Burny Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants
description	Abstract Differences in innate immune ‘imprinting’ between vaccine adjuvants may mediate dissimilar effects on the quantity/quality of persisting adaptive responses. We compared antibody avidity maturation, antibody/memory B cell/CD4+ T cell response durability, and recall responses to non-adjuvanted fractional-dose antigen administered 1-year post-immunization (Day [D]360), between hepatitis B vaccines containing Adjuvant System (AS)01B, AS01E, AS03, AS04, or Alum (NCT00805389). Both the antibody and B cell levels ranked similarly (AS01B/E/AS03 > AS04 > Alum) at peak response, at D360, and following their increases post-antigen recall (D390). Proportions of high-avidity antibodies increased post-dose 2 across all groups and persisted at D360, but avidity maturation appeared to be more strongly promoted by AS vs. Alum. Post-antigen recall, frequencies of subjects with high-avidity antibodies increased only markedly in the AS groups. Among the AS, total antibody responses were lowest for AS04. However, proportions of high-avidity antibodies were similar between groups, suggesting that MPL in AS04 contributes to avidity maturation. Specific combinations of immunoenhancers in the AS, regardless of their individual nature, increase antibody persistence and avidity maturation.
format	article
author	Sonia Budroni Francesca Buricchi Andrea Cavallone Patricia Bourguignon Magalie Caubet Vincent Dewar Ugo D’Oro Oretta Finco Nathalie Garçon Mohamed El Idrissi Michel Janssens Geert Leroux-Roels Arnaud Marchant Tino Schwarz Pierre Van Damme Gianfranco Volpini Robbert van der Most Arnaud M. Didierlaurent Wivine Burny
author_facet	Sonia Budroni Francesca Buricchi Andrea Cavallone Patricia Bourguignon Magalie Caubet Vincent Dewar Ugo D’Oro Oretta Finco Nathalie Garçon Mohamed El Idrissi Michel Janssens Geert Leroux-Roels Arnaud Marchant Tino Schwarz Pierre Van Damme Gianfranco Volpini Robbert van der Most Arnaud M. Didierlaurent Wivine Burny
author_sort	Sonia Budroni
title	Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants
title_short	Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants
title_full	Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants
title_fullStr	Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants
title_full_unstemmed	Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants
title_sort	antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/44c6adaabe024a3786359666e5ee13fc
work_keys_str_mv	AT soniabudroni antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT francescaburicchi antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT andreacavallone antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT patriciabourguignon antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT magaliecaubet antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT vincentdewar antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT ugodoro antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT orettafinco antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT nathaliegarcon antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT mohamedelidrissi antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT micheljanssens antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT geertlerouxroels antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT arnaudmarchant antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT tinoschwarz antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT pierrevandamme antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT gianfrancovolpini antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT robbertvandermost antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT arnaudmdidierlaurent antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants AT wivineburny antibodyaviditypersistenceandresponsetoantigenrecallcomparisonofvaccineadjuvants
_version_	1718385567491686400

Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants

Ejemplares similares